Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PHAS

PhaseBio Pharmaceuticals (PHAS) Stock Price, News & Analysis

PhaseBio Pharmaceuticals logo

About PhaseBio Pharmaceuticals Stock (NASDAQ:PHAS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
9.65 million shs
Average Volume
848,888 shs
Market Capitalization
$3.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PHAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PHAS Stock News Headlines

MedPharm appoints Bill Humphries as new CEO
A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.tc pixel
PhaseBio Pharmaceuticals Inc.
PhaseBio Pharmaceuticals, Inc. (PHASQ)
Alcami Announces CEO Transition
See More Headlines

PHAS Stock Analysis - Frequently Asked Questions

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) released its earnings results on Wednesday, November, 10th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.07. The business earned $0.34 million during the quarter, compared to analysts' expectations of $2.67 million.

PhaseBio Pharmaceuticals (PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that PhaseBio Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM), VBI Vaccines (VBIV), Oncobiologics (OTLK), Viking Therapeutics (VKTX) and Anavex Life Sciences (AVXL).

Company Calendar

Last Earnings
11/10/2021
Today
8/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PHAS
CIK
1169245
Fax
N/A
Employees
60
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$131.07 million
Net Margins
-12,572.13%
Pretax Margin
-12,572.13%
Return on Equity
N/A
Return on Assets
-174.38%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.47
Quick Ratio
0.47

Sales & Book Value

Annual Sales
$818 thousand
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.93) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
49,858,000
Free Float
44,922,000
Market Cap
$3.50 million
Optionable
Not Optionable
Beta
2.57

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:PHAS) was last updated on 9/1/2025 by MarketBeat.com Staff
From Our Partners